Lonza biopharma plant ahead of schedule

Published: 4-Apr-2003

Construction has begun on Lonza's new biopharmaceuticals manufacturing plant at its Visp site in Switzerland.


Construction has begun on Lonza's new biopharmaceuticals manufacturing plant at its Visp site in Switzerland.

The new plant represents an investment of more than Sfr100m (€67.4m) and will create at least 100 new jobs over the next two years. It will house two segregated fermentation and down-stream processing lines capable for the cGMP manufacture of biologics medicines based on microbial cell technologies. A 15,000l line will be operational by the first quarter of 2005, while the smaller scale 1,000l line will be ready for operation by November 2003, one year ahead of schedule.

'We are extremely pleased to offer our customers access to our 1,000l microbial biologics plant by the end of this year,' said Rene Imwinkelried, head of Lonza Biotec. 'This underscores our commitment to strengthen our leadership position in biotechnology custom manufacturing services. By quarter four of 2003 the expansion of our process research and development facilities will be completed as well.'

You may also like